CVS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CVS Health Corp is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong financial performance, positive catalysts from Medicare payment increases, and favorable analyst ratings, making it a solid investment opportunity.
The MACD histogram is positive at 0.451, indicating a bullish trend, though it is contracting. RSI at 53.662 is neutral, and moving averages are converging, suggesting no immediate breakout. The stock is trading near its pivot level of 76.201, with resistance at 79.051 and support at 73.352.
Analysts have raised price targets and reiterated Outperform ratings, citing improved profitability from Medicare payment increases.
Recent news highlights a $13 billion boost from a 2.5% Medicare payment rate increase, improving earnings expectations and stock valuation.
Financial performance in Q4 2025 showed strong revenue growth (8.17% YoY) and a significant increase in net income (79.01% YoY).
Gross margin dropped by 2.73% YoY in Q4 2025, which could indicate cost pressures.
No significant hedge fund or insider trading activity, suggesting limited immediate institutional interest.
In Q4 2025, CVS Health reported revenue of $105.69 billion, up 8.17% YoY. Net income surged to $2.94 billion, up 79.01% YoY, with EPS increasing to $2.29, up 76.15% YoY. However, gross margin declined to 12.84%, down 2.73% YoY.
Analysts are generally positive on CVS Health, with multiple firms maintaining Outperform ratings and raising price targets. Recent upgrades highlight the company's diversification and improved profitability outlook from Medicare payment increases.
